Effects of poly (ADP-ribose) polymerase inhibitor on early peripheral neuropathy in streptozotocin-diabetic rat

ObjectiveTo explore the effects and mechanisms of poly (ADP-ribose) polymerase (PARP) inhibitor 3-aminobenzamide on nerve lesions in streptozotocin-diabetic rats.MethodsExperimental rats were divided into normal control group (NC group), diabetic control group (DC group) and diabetic group treated with 3-aminobenzamide (DT group). Nerve conduction velocity (NCV). serum superoxide dismutase (SOD) activity and serum malondialdehyde (MDA) concentration, phosphocreatine (Per). creatine (Cr) concentration in sciatic nerves were evaluated after 4 weeks.ResultsSOD, Per activity, and NCV were higher (P < 0.05) and MDA concentration were significantly lower in DT group, compared with DC group (P < 0.01). Meanwhile, ATP and Cr in sciatic nerves were similar in DT group, compared with DC group (P > 0.05).Conclusion3-aminobenzamide could alleviate the established functional and metabolic abnormalities of early DPN in the streptozotocin-induced diabetic rat models, which provided a novel approach for prevention and treatment of diabetic neuropathy.